AU2001247965A1 - Therapeutic and diagnostic methods for ulcerative colitis and associated disorders - Google Patents

Therapeutic and diagnostic methods for ulcerative colitis and associated disorders

Info

Publication number
AU2001247965A1
AU2001247965A1 AU2001247965A AU4796501A AU2001247965A1 AU 2001247965 A1 AU2001247965 A1 AU 2001247965A1 AU 2001247965 A AU2001247965 A AU 2001247965A AU 4796501 A AU4796501 A AU 4796501A AU 2001247965 A1 AU2001247965 A1 AU 2001247965A1
Authority
AU
Australia
Prior art keywords
cep
htm
htm5
cells
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001247965A
Other languages
English (en)
Inventor
Kiron M. Das
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Medicine and Dentistry of New Jersey
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of AU2001247965A1 publication Critical patent/AU2001247965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
AU2001247965A 2000-02-08 2001-02-08 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders Abandoned AU2001247965A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18135600P 2000-02-08 2000-02-08
US60181356 2000-02-08
PCT/US2001/040066 WO2001058927A1 (en) 2000-02-08 2001-02-08 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders

Publications (1)

Publication Number Publication Date
AU2001247965A1 true AU2001247965A1 (en) 2001-08-20

Family

ID=22663939

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001247965A Abandoned AU2001247965A1 (en) 2000-02-08 2001-02-08 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders

Country Status (6)

Country Link
US (3) US6800446B2 (ja)
EP (1) EP1257563A4 (ja)
JP (1) JP2003522196A (ja)
AU (1) AU2001247965A1 (ja)
CA (1) CA2400699A1 (ja)
WO (1) WO2001058927A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029786A1 (en) * 2002-05-08 2004-02-12 Das Kiron M Treatment of ulcerative colitis by introducing CEP antigen composition
AU2003239087A1 (en) 2002-06-25 2004-01-06 Index Pharmaceuticals Ab Method and kit for the diagnosis of ulcerative colitis
WO2005067708A2 (en) 2004-01-14 2005-07-28 Daniolabs Limited Zebrafish model for autoimmune diseases
DK2223121T3 (da) 2007-12-20 2012-10-22 Index Diagnostics Ab Publ Fremgangsmåde og kit til anvendelse ved differentiering mellem ibd og ibs og yderligere skelnen mellem ibd-sygdomstyper
WO2017138008A2 (en) * 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US4914188A (en) * 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5869048A (en) * 1995-05-09 1999-02-09 University Of Medicine & Dentistry Method of treating ulcerative colitis with a monoclonal antibody
US6605276B1 (en) 1995-05-09 2003-08-12 University Of Medicine & Dentistry Of New Jersey Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms
WO1996035449A1 (en) 1995-05-09 1996-11-14 University Of Medicine & Dentistry Monoclonal antibodies for the treatment of ulcerative colitis

Also Published As

Publication number Publication date
EP1257563A4 (en) 2003-03-26
JP2003522196A (ja) 2003-07-22
WO2001058927A1 (en) 2001-08-16
US7122336B2 (en) 2006-10-17
US20020013259A1 (en) 2002-01-31
US6800446B2 (en) 2004-10-05
EP1257563A1 (en) 2002-11-20
US20070032426A1 (en) 2007-02-08
CA2400699A1 (en) 2001-08-16
US20030236182A1 (en) 2003-12-25

Similar Documents

Publication Publication Date Title
EP2758076B1 (en) Combination therapy using immunoglobulin and c1-inhibitor
Lehmann et al. Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis
US20070032426A1 (en) Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
Kesari et al. Externalization of tropomyosin isoform 5 in colon epithelial cells
Ding et al. Prostaglandin, tumor necrosis factor α and neutrophils: causative relationship in indomethacin-induced stomach injuries
US20070149450A1 (en) Method for reducing levels of c-reactive protein
JP2004514649A (ja) Ｎｕｒｒサブファミリーの核転写因子の抑制による疾患に対する治療アプローチ
KR19990066672A (ko) 히스톤을 함유하는 류마티스 관절염 치료제 조성물
CA2758829C (en) Method of treating demyelinating disease
US20080045463A1 (en) Methods For Lowering Hif-1 Mediated Gene Expression
WO1988007869A2 (en) ANTI-INTERFERON-gamma-ANTIBODIES AND THEIR THERAPEUTIC APPLICATION
JPH07170998A (ja) ＮＦ−κＢの調節方法
EP4087585A1 (en) Compositions and methods for preventing recurrence of cancer
US5869048A (en) Method of treating ulcerative colitis with a monoclonal antibody
WO2020014208A1 (en) Camk4 inhibitors for restoration of podocyte function in kidney disease
FR2829768A1 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
US20040096450A1 (en) Methods and compositions for treating diseases associated with increased Fas-ligand titers
WO2005055997A1 (ja) 炎症性疾患の治療及び予防用医薬組成物
US5871739A (en) Pharmaceutical composition
US20230053129A1 (en) Compound for the treatment of the hemolytic-uremic syndrome
EP1140118A1 (en) Cyclic adenosine diphosphate ribose analogues for modulating t cell activity
US20240009155A1 (en) Use of short chain fatty acids in cancer prevention
JP2023178240A (ja) 自己免疫疾患の抑制用医薬組成物、自己抗体の産生抑制剤、及び異常免疫の調節剤
KR20240026952A (ko) S-하이드록시클로로퀸을 사용한 항인지질증후군의 치료
WO2024054558A2 (en) Compositions and methods for amelioration of symptoms associated with clec16a dysfunction or loss